Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines
Final decision from the European Commission is anticipated within the coming months
The trademark rights for these brands will be transferred to Lupin by March next year.
The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
This product is indicated in coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity.
The successful completion of RRA assessment by the USFDA, would enable company to open up its business in the USA market
Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate
Partnership to supercharge LVMH Recherche with Integrated Biosciences’ innovative AI and synthetic biology platform for targeting skin aging
Based on data, 1.75 mg/kg dose established as recommended dose for Phase 3 trial of this investigational antibody-drug conjugate
Subscribe To Our Newsletter & Stay Updated
